Increased Muscle Activity During Rapid Eye Movement Sleep Correlates with Decrease of Striatal Presynaptic Dopamine Transporters. IPT and IBZM SPECT Imaging in Subclinical and Clinically Manifest Idiopathic REM Sleep Behavior Disorder, Parkinson's Disease, and Controls

Eisensehr, Ilonka; Linke, R.; Tatsch, Klaus; Kharraz, Bita; Gildehaus, Josef F; Wetter, Christian T; Trenkwalder, Claudia; Schwarz, Johannes; Noachtar, Soheyl

doi:10.1093/sleep/26.5.507

Cited by 231 publications

(123 citation statements)

References 21 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…However, iRBD is a prodrome of PD, and the fact that RBD frequently appears secondary to PD indicates a possible connection between dopamine and RBD. 29 Furthermore, patients with iRBD show nigrostriatal dopaminergic dysfunction manifested in SPECT imaging as reduced striatal dopamine transporter levels, 30,31 reduced striatal dopamine transmission, 32 and decreased putamen dopamine uptake. 33 In addition, dopamine depletion engenders increased muscle tone during REM sleep, and RBD onset was affected by an imbalance of DA levels in an MPTP model of PD.…”

Section: Discussionmentioning

confidence: 99%

Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease

Wang

Yang

et al. 2016

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

Study Objectives: REM sleep behavior disorder (RBD) is a common manifestation of Parkinson disease (PD). In this study, we assessed the effects of rotigotine transdermal patch on RBD features in patients with PD. Methods:In this prospective open-label study, eleven PD patients with untreated RBD were administered rotigotine patches for up to seven months to ameliorate their parkinsonism. The severities of their RBD symptoms before and after rotigotine therapy were evaluated through patient and bed partner interviews, a validated evaluation scale (REM sleep behavior disorder questionnaire-Hong Kong, RBDQ-HK), and blinded assessments based on videopolysomnographic (VPSG) measure. Results: Rotigotine improved parkinsonism and subjective sleep quality in PD patients with RBD. The RBDQ-HK total score, especially the Factor 2 score, was decreased, which demonstrated that the subjective severity of RBD symptoms was improved after rotigotine treatment, especially the frequency and severity of abnormal RBD-related motor behaviors. The VPSG analyses showed that the total sleep time (TST) and stage 1% were increased and that the PLMS index was decreased. However, no differences in the RBD-related sleep measures were observed. Conclusions: The improved RBD symptoms and VPSG measures of PD patients in this study (TST, stage 1%, and PLMS index) suggest that, in PD, rotigotine may partially improve RBD-related symptoms. Rotigotine should be considered to be an optional drug for the treatment of RBD symptoms in PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease

Wang

Yang

et al. 2016

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

show abstract

“…There are a few recent reports on RBD associated with spinocerebellar atrophy type 3 (Machado-Joseph disease). [63][64][65] As noted above, numerous cases of RBD have been reported in conjunction with MSA, 3,22,23,27,[66][67][68][69][70][71][72] PD, 3,11,22,[24][25][26][27][30][31][32][33][34][35]73 and DLB. 1,10,15,41,45,[47][48][49][50][51][52][53]55,59,60,74 Although frequency data on the presence of RSWA and RBD in the neurodegenerative disorders is based on relatively small numbers of patients thus far, the presence of each in MSA has been reported to be 90% to 95% for RSWA and 68% to 90% for RBD, 66,67 and presence of each in PD is approximately 58% for RSWA and 33% for RBD.…”

Section: The Rbd-synucleinopathy Associationmentioning

confidence: 99%

“…Dopaminergic dysfunction has been implicated in RBD pathophysiology based on anatomic, 13 pharmacologic, 11 and functional neuroimaging studies, 35,82,83 yet there is no convincing evidence that dopaminergic dysfunction is the primary cause of RBD. A recent analysis using synuclein immunocytochemistry in incidental and symptomatic Parkinson's disease cases reveals striking overlap between the presumed brainstem nuclei involved in RBD pathophysiology and PD pathophysiology.…”

Section: Brainstem Anatomy Of Rbd and Synucleinopathy Pathologymentioning

confidence: 99%

REM Sleep Behavior Disorder in Parkinson’s Disease and Dementia with Lewy Bodies

Boeve

Silber

Ferman

2004

J Geriatr Psychiatry Neurol

208

106

View full text Add to dashboard Cite

Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia manifested by vivid, often frightening dreams associated with simple or complex motor behavior during REM sleep. Patients appear to "act out their dreams," in which the exhibited behaviors mirror the content of the dreams. Management of RBD involves counseling about safety measures in the sleep environment; in those at risk for injury, clonazepam and/or melatonin is usually effective. In this article, the authors present a detailed review of the clinical and polysomnographic features, differential diagnosis, diagnostic criteria, management strategies, and pathophysiologic mechanisms of RBD. They then review the literature and their institutional experience of RBD associated with neurodegenerative disease, particularly Parkinson's disease and dementia with Lewy bodies. The evolving data suggests that RBD may have clinical diagnostic and pathophysiologic significance in isolation and when associated with neurodegenerative disease. (J Geriatr Psychiatry Neurol 2004; 17:146-157)

show abstract

“…Idiopathic RBD usually presents in the sixth or seventh decade and predominates in males. In these patients cognitive (visuospatial, constructive) disturbances, slowing of occipital EEG activity and a decreased striatal dopaminergic availability during wakefulness have been reported [74][75][76][77]. A significant proportion of patients with idiopathic RBD develop in the later course a Parkinsonian disorder [78].…”

Section: Rem Sleep Behaviour Disorder (Rbd)mentioning

confidence: 99%

Dreaming: a neurological view

2005

Swiss Arch Neurol Psychiatr

View full text Add to dashboard Cite

SummaryBassetti CL, Bischof M,Valko P. Dreaming: a neurological view. Schweiz Arch Neurol Psychiatr 2005; 156:399-414. Dreaming is the mental activity of REM (and less commonly NREM) sleep. It is characterised by a perception of self, inner and outer world that is distinct from that of wakefulness. Neurophysiological and neuroimaging studies suggest that dreaming arises from activation of brainstem, thalamo-limbic and medial temporo-occipital areas and inactivation of dorsolateral prefrontal areas.Dream abnormalities in neurological disorders have poorly been studied. They include a reduction/cessation of dreaming (Charcot-Wilbrand syndrome), an increase in dream frequency, changes in dream contents and accompaniments (including REM sleep behaviour disorder) and the occurrence of dream-like experiences (hallucinations) during wakefulness and wake-sleep/sleep-wake transitions. Dream changes in association with neurological conditions including primary sleep disorders (e.g. narcolepsy, REM sleep behaviour disorder [RBD], nightmares), stroke and Parkinson's syndrome are reviewed.Assessment of altered dreaming and dreamlike experiences can be of clinical significance because of their diagnostic and therapeutic implications (RBD, hallucinations), prognostic significance (hallucinations) and distress that they can have for patients and their bed partners (e.g. nightmares, hallucinations, RBD). In addition, systematic studies of dream and dream-like experiences are expected to offer unique insights into the brain, mind and emotions of neurological patients.

show abstract

Increased Muscle Activity During Rapid Eye Movement Sleep Correlates with Decrease of Striatal Presynaptic Dopamine Transporters. IPT and IBZM SPECT Imaging in Subclinical and Clinically Manifest Idiopathic REM Sleep Behavior Disorder, Parkinson's Disease, and Controls

Abstract: This study suggests that there is a continuum of reduced striatal dopamine transporters involved in the pathophysiologic mechanisms causing increased muscle activity during REM sleep in patients with subclinical RBD.

Cited by 231 publications

References 21 publications

Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease

Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease

REM Sleep Behavior Disorder in Parkinson’s Disease and Dementia with Lewy Bodies

Dreaming: a neurological view

Contact Info

Product

Resources

About